Education
About Us
Working with TipRanks
Follow Us
Neurogene (NGNE)
NASDAQ:NGNE
NGNE Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NGNE Stock 12 Month Forecast
Average Price Target
$58.00
▲(196.98% Upside)
| Highest Price Target$70.00 | Average Price Target$58.00 | Lowest Price Target$46.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Buy
―
Reiterated
11/17/25
Promising Outlook for Neurogene's NGN-401 in Rett Syndrome Treatment: Analyst Recommends 'Buy'We do not see the ICV procedure as a bottleneck for NGN-401 commercial adoption as they are commonly performed. The surgical procedure takes approximately one hour and is routinely performed, with approximately 30,000 ICV procedures in the U.S. annually. Management anticipates Rett centers of excellence could be initial adopters of NGN-401 commercially, with other pediatric neurology centers with gene therapy experience being potential second-wave adopters.
H.C. Wainwright
$70
Buy
258.42%
Upside
Reiterated
11/17/25
Neurogene's NGN-401: Strong Clinical Results and Market Misalignment Justify Buy RatingValuation and Risks. Using a 13% discount rate and 1% terminal growth rate, our discounted cash flow (DCF)-based analysis has resulted in an estimated enterprise value of $1.6B. We ascribe a 55% probability of approval to NGN-401 in Rett syndrome. Assuming 25M fully-diluted shares outstanding, we derive a 12-month price objective of $70 per share, which includes the forecast cash position. We conservatively do not model any expansion into other indications or pipeline programs beyond NGN-401, which may drive upside to our valuation.
TD Cowen
―
Buy
―
Reiterated
11/16/25
Stifel Nicolaus
$46
Buy
135.54%
Upside
Reiterated
11/13/25
Craig-Hallum
―
Buy
―
Reiterated
11/13/25
Leerink Partners
$72→$70
Buy
258.42%
Upside
Reiterated
08/12/25
Neurogene's Clinical Progress and Financial Resilience Underpin Buy Rating Despite Regulatory ChallengesWe update our model for financial disclosures, modestly increase R&D for pivotal costs and nudge EU/RoW launch to 2030 (from 2029) as we await clarity on OUS regulatory pathway, which decreases our PT to $70 (from $72). Reiterate OP.
Robert W. Baird
$38→$24
Hold
22.89%
Upside
Downgraded
05/16/25
BMO Capital
$45→$16
Buy
-18.07%
Downside
Reiterated
04/14/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Buy
―
Reiterated
11/17/25
Promising Outlook for Neurogene's NGN-401 in Rett Syndrome Treatment: Analyst Recommends 'Buy'We do not see the ICV procedure as a bottleneck for NGN-401 commercial adoption as they are commonly performed. The surgical procedure takes approximately one hour and is routinely performed, with approximately 30,000 ICV procedures in the U.S. annually. Management anticipates Rett centers of excellence could be initial adopters of NGN-401 commercially, with other pediatric neurology centers with gene therapy experience being potential second-wave adopters.
H.C. Wainwright
$70
Buy
258.42%
Upside
Reiterated
11/17/25
Neurogene's NGN-401: Strong Clinical Results and Market Misalignment Justify Buy RatingValuation and Risks. Using a 13% discount rate and 1% terminal growth rate, our discounted cash flow (DCF)-based analysis has resulted in an estimated enterprise value of $1.6B. We ascribe a 55% probability of approval to NGN-401 in Rett syndrome. Assuming 25M fully-diluted shares outstanding, we derive a 12-month price objective of $70 per share, which includes the forecast cash position. We conservatively do not model any expansion into other indications or pipeline programs beyond NGN-401, which may drive upside to our valuation.
TD Cowen
―
Buy
―
Reiterated
11/16/25
Stifel Nicolaus
$46
Buy
135.54%
Upside
Reiterated
11/13/25
Craig-Hallum
―
Buy
―
Reiterated
11/13/25
Leerink Partners
$72→$70
Buy
258.42%
Upside
Reiterated
08/12/25
Neurogene's Clinical Progress and Financial Resilience Underpin Buy Rating Despite Regulatory ChallengesWe update our model for financial disclosures, modestly increase R&D for pivotal costs and nudge EU/RoW launch to 2030 (from 2029) as we await clarity on OUS regulatory pathway, which decreases our PT to $70 (from $72). Reiterate OP.
Robert W. Baird
$38→$24
Hold
22.89%
Upside
Downgraded
05/16/25
BMO Capital
$45→$16
Buy
-18.07%
Downside
Reiterated
04/14/25
Best Analysts Covering Neurogene
1 Month
xxx
Success Rate
7/12 ratings generated profit
Average Return
+6.08%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +6.08% per trade.
3 Months
xxx
Success Rate
9/10 ratings generated profit
Average Return
+24.80%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 90.00% of your transactions generating a profit, with an average return of +24.80% per trade.
1 Year
Success Rate
8/15 ratings generated profit
Average Return
+0.80%
reiterated a buy rating last month
Copying Paul Matteis's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +0.80% per trade.
2 Years
xxx
Success Rate
6/15 ratings generated profit
Average Return
-14.57%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -14.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NGNE Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
11
10
8
4
6
Buy
10
8
4
7
10
Hold
1
0
1
1
1
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
18
13
12
17
Each month's total comprises the sum of three months' worth of ratings.
NGNE Financial Forecast
NGNE Stock Forecast FAQ
What is NGNE’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurogene’s 12-month average price target is 58.00.
What is NGNE’s upside potential, based on the analysts’ average price target?
Neurogene has 196.98% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NGNE a Buy, Sell or Hold?
Neurogene has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Neurogene’s price target?
The average price target for Neurogene is 58.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $46.00. The average price target represents 196.98% Increase from the current price of $19.53.
The highest analyst price target is $70.00 ,the lowest forecast is $46.00. The average price target represents 196.98% Increase from the current price of $19.53.
What do analysts say about Neurogene?
Neurogene’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of NGNE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.